Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
27 January 2021
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
Immunicum AB (publ; IMMU.ST) announced today that its in-house research and process development activities will move into a new facility at the Leiden Bio Science Park, the Netherlands. The Company has signed a long-term lease with developer Kadans Science Partner for approximately 1,100 square meters of laboratory and office space in the Plus Ultra Leiden, a new building currently under development. Furthermore, Immunicum has the option to rent an additional 1,100 square meters to further support its future growth. The new location, that is expected to be fully commissioned in 2022, will serve as Immunicum s core research and development hub.
Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial
17 December 2020
Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial Topline results on safety and dosing from Phase Ib portion of trial expected during Q3 2021 Phase II portion of trial can initiate following selection of dose regimen from Phase Ib trial
Immunicum AB (publ; IMMU.ST) announced today the completion of patient recruitment for the Phase Ib portion of the ongoing ILIAD (ILIxadencel in combination with checkpoint inhibitors in ADvanced cancer patients) trial. The primary objective of the Phase Ib study is to evaluate the safety and tolerability as well as define the dose regimen for Immunicum s lead cell-based candidate, ilixadencel, in combination with the checkpoint inhibitor (CPI), Keytruda (pembrolizumab), in a total of 21 patients.